Objectif Sudden cardiac arrest affects up to 1 million people in US and Europe per year, being the 3rd leading cause of death globally. Despite international medical efforts, 9 out of 10 people will die after a cardiac arrest (average survival rate 10.6%). In the European Union, cardiovascular disease costs to the economy more than €192 billion annually.Emergency teams suffer the most with the extremely high mortality and morbidity rates due to cardiac arrest worldwide. Currently, medical assistive devices play a limited role on teams’ diagnostics and therapeutic actions during rescue emergencies. Nevertheless, the defibrillation/CPR devices global market was valued at $1.7B in 2014 and is expected to grow until 2019 with a CAGR of 8% reflecting a strong market demand.pCPR is a portable, precise and personalized medical device to properly assist emergency teams during sudden cardiac arrest emergencies. It consists of a thoracic pad with sensors that doctors, nurses and paramedics apply directly to the patient linked to a new monitor display and defibrillator to support and guide their critical decision-making and patient-specific emergent therapy.The value proposition of pCPR is based on emergency end-users’ feedback and experts’ calls for action, through a lean fast-to-market strategy, delivering unique selling points: - Adaptive physiological feedback (disruptive innovation);- Focus on cerebral oxygen saturation, temperature and tcCO2 (new target indicators);- Clinical reasoning algorithms (cognitive aids at point of care);- Cardiac/Neurologic outcomes guidance (assisting device);- Data management for Quality control (analytics);- Exclusively non-invasive sensors (technology);pCPR wants to be one of the leading assistive device for emergency teams worldwide in a 5-years’ time frame, building upon its patented thoracic pad and combined sensing capabilities to deliver better cost-effective patient care and health outcomes, namely the cardiac arrest survival rate. Champ scientifique medical and health sciencesclinical medicineemergency medicinemedical and health sciencesclinical medicinecardiology Programme(s) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.4. - Active ageing and self-management of health H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument H2020-EU.3.1.6. - Health care provision and integrated care Thème(s) SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well Appel à propositions H2020-SMEInst-2016-2017 Voir d’autres projets de cet appel Sous appel H2020-SMEINST-1-2016-2017 Régime de financement SME-1 - SME instrument phase 1 Coordinateur MEDSIMLAB LDA Contribution nette de l'UE € 50 000,00 Adresse RUE ALEXANDRE HERCULANO 32 R/C SE NOVA SANTA CRUZ ALMEDINA E SAO BARTOLOMEU 3000 019 COIMBRA Portugal Voir sur la carte PME L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention. Oui Région Continente Centro (PT) Região de Coimbra Type d’activité Private for-profit entities (excluding Higher or Secondary Education Establishments) Liens Contacter l’organisation Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 71 429,00
